In addition, biomarkers reflecting myocardial fibrosis, such as Gal-3 and sST2, as well as those reflecting obesity and CKD, are involved in the development and progression of HFpEF and can be used for optimal risk stratification. The gene discussed is LGALS3; the disease is obesity disorder.